Asset Breakdown
21.77 Million
Total Assets
Current Assets
10.53 Million
Assets Non Current
Continue to hold NanoViricides?
 | By Vlad Skutelnik | Macroaxis Story |
Today's article will go over NanoViricides Inc. We will look into why albeit cyclical market disturbance, the long term basic indicators of the company are still strong. The firm current daily volatility is 9.55 percent, with a beta of -0.85 and an alpha of 0.91 over DOW. NanoViricides NEW Piotroski F Score is 3 - Frail. NanoViricides Inc is relatively risky given 1 month investment horizon. NanoViricides NEW has Sharpe Ratio of 0.11, which conveys that the firm had 0.11% of return per unit of risk over the last month. Our standpoint towards estimating the risk of a stock is to use both market data as well as company specific technical data. We were able to interpolate and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.1% are justified by taking the suggested risk. Use NanoViricides NEW mean deviation of 6.17, downside deviation of 6.41, and risk adjusted performance of 0.1727 to evaluate company specific risk that cannot be diversified away.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
NanoViricides Inc currently holds 1.18 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest NanoViricides NEW is not taking enough advantage from borrowing. This firm currently holds 1.18 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the entity is not taking enough advantage from borrowing. The company has a current ratio of 2.85, suggesting that it is liquid enough and is able to pay its financial obligations when due. NanoViricides financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of NanoViricides, including all of NanoViricides's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of NanoViricides assets, the company is considered highly leveraged. Understanding the composition and structure of overall NanoViricides debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
Watch out for price decline
Please consider monitoring NanoViricides on a daily basis if you are holding a position in it. NanoViricides is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as NanoViricides stock to be traded above the $1 level to remain listed. If NanoViricides stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Understanding NanoViricides Total Debt
NanoViricides liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. NanoViricides has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on NanoViricides balance sheet include debt obligations and money owed to different NanoViricides vendors, workers, and loan providers. Below is the chart of NanoViricides main long-term debt accounts currently reported on its balance sheet. You can use NanoViricides financial leverage analysis tool to get a better grip on understanding its financial positionHow important is NanoViricides's Liquidity
NanoViricides financial leverage refers to using borrowed capital as a funding source to finance NanoViricides ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NanoViricides financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to NanoViricides' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of NanoViricides' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between NanoViricides's total debt and its cash.
Another angle On NanoViricides
Net Loss for the year was (13.78 M) with profit before overhead, payroll, taxes, and interest of 0. NanoViricides Inc Earnings before Tax is somewhat stable at the moment.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NanoViricides. Please refer to our Terms of Use for any information regarding our disclosure principles.